Peter – Glaucoma

Healthcare systems are strained to the breaking point as our population ages. Farmland is diminishing as the population swells. Climate change is reducing crop yields as more people go hungry every day. Today, and in the decades to come, new solutions must be discovered to provide quality health and food for at least ten billion people.

We feel it is our responsibility to set new benchmarks

Leaps by Bayer is spearheading a movement to make paradigm-shifting advances in the life sciences – targeting the breakthroughs that could fundamentally change the world for the better. Much of what we are aiming to achieve is not yet possible. Setbacks and failures are to be expected in dealing with such ambitious targets.

But with a 150-year history in the life sciences and capabilities across healthcare and agriculture, Bayer is able to see the bigger picture. We feel it is our responsibility to set new benchmarks; to find the courage to begin where others resist; and to drive breakthrough innovation. And we will not do it alone: we will collaborate with the world’s smartest minds in biotech.

Learn more about our mission


Elmar – Heart defect

Our joint ventures Collaborating with the world’s smartest minds in biotech


eGenesis is a biotechnology company that utilizes breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage. Their goal is to make available safe and reliable xeno organs, tissues, and cells to patients in need and advance the field of transplantation. eGenesis uses gene-editing tools, such as CRISPR, to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. eGenesis is advancing an initial product toward the clinic for a kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy.